The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a caution for individuals using medications such as Ozempic, Wegovy, Rybelsus, or Mounjaro. The health authority shared this alert on social media urging those experiencing severe reactions to GLP-1 medicine to take action.
GLP-1s, known as glucagon-like peptide-1 receptor agonists, are drugs designed to enhance the feeling of fullness by imitating a hormone released after meals, as per information on the Government’s website. MHRA emphasized the importance of reporting any side effects, particularly acute pancreatitis, to facilitate research for better comprehension and for ensuring safer prescription practices in the future.
The MHRA’s complete message emphasized the need to identify individuals at risk due to severe reactions to GLP-1 medications. It encouraged reporting cases of acute pancreatitis associated with these drugs to the Yellow Card system, potentially leading to participation in the Yellow Card Biobank program by MHRA and Genomics England to explore how genetics might impact side effects and improve future prescription safety.
The Yellow Card Biobank initiative, a collaboration between MHRA and Genomics England, aims to enhance understanding of how a patient’s genetic composition could increase the likelihood of adverse reactions to medications. Insights from this research will assist healthcare professionals in preventing harmful side effects by ensuring that patients are prescribed the most appropriate medications based on their genetic characteristics.
In the UK, various GLP-1 medications are authorized, such as semaglutide under the brand names Wegovy, Ozempic, and Rybelsus, tirzepatide (Mounjaro), and liraglutide marketed under different brands. The term “licensed” indicates that these drugs have undergone thorough evaluation by the UK medicines regulator, MHRA, and have been deemed safe and effective for specific purposes. However, the safety and effectiveness of these medications have not been evaluated for uses beyond their licensed indications.
GLP-1 medications are approved for treating specific medical conditions and should only be used under professional guidance for individuals with obesity or diabetes, not for cosmetic weight loss purposes.